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A B S T R A C T
The EU human biomonitoring initiative, HBM4EU, aims to co-ordinate and advance human biomonitoring
(HBM) across Europe. Within its remit, the project is gathering new, policy relevant, EU-wide data on occu-
pational exposure to relevant priority chemicals and developing new approaches for occupational biomoni-
toring. In this manuscript, the hexavalent chromium [Cr(VI)] study design is presented as the first example of
this HBM4EU approach. This study involves eight European countries and plans to recruit 400 workers per-
forming Cr(VI) surface treatment e.g. electroplating or stainless steel welding activities. The aim is to collect new
data on current occupational exposure to Cr(VI) in Europe and to test new methods for Cr biomonitoring,
specifically the analysis of Cr(VI) in exhaled breath condensate (EBC) and Cr in red blood cells (RBC) in addition
to traditional urinary total Cr analyses. Furthermore, exposure data will be complemented with early biological
effects data, including genetic and epigenetic effects. Personal air samples and wipe samples are collected in
parallel to help informing the biomonitoring results. We present standard operational procedures (SOPs) to
support the harmonized methodologies for the collection of occupational hygiene and HBM samples in different
countries.
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1. Introduction
The EU human biomonitoring initiative (HBM4EU, www.hbm4eu.
eu/about-hbm4eu/) is a European Joint Programme, which aims to
harmonize and use biomonitoring to understand human exposure to
chemicals in the environment, in occupational settings or through the
use of consumer products and the related health risks, in order to im-
prove chemical risk management and to support policy making
(Ganzleben et al., 2017). It is funded by the European Commission and
national governments and includes experts from 28 countries and
European Environment Agency (EEA). It runs from 2017 to 2021.
Human biomonitoring (HBM) provides important data on the
combined exposure via all routes of exposure. It can complement
measurements in food and environmental matrices and provide in-
formation on the effectiveness of preventive and protective measures.
Thus, HBM has been considered as a beneficial approach for the health
risk management e.g. under EU REACH regulation (Boogaard et al.,
2011). Occupational exposures to specific chemicals may, in many in-
stances, be several times higher than environmental exposures experi-
enced by the general population. However, a typical challenge in oc-
cupational studies is the low number of workers that can be recruited in
national studies. Furthermore, the studies performed by different re-
searchers in individual countries are usually not aligned with respect to
sampling, analytical methodologies or data collection, which compli-
cates the comparison of the findings and use of the data in regulatory
risk assessment at the European level. Combining national surveys
using harmonized study designs and methodologies can potentially
greatly improve the information collected and bring EU-added value for
the data collected in different European countries as demonstrated in
the earlier DEMOCOPHES project (www.eu-hbm.info/democophes).
One of the most important aims of the whole HBM4EU project is the
harmonization of methodologies and standardized collection of the data
useful for EU decision making. In line with these overall goals, herein
we present a multicenter study that intends to characterize occupa-
tional exposure to hexavalent chromium (Cr (VI)) in industrial settings
across Europe.
Hexavalent chromium is an important occupational carcinogen and
has been shown to cause lung cancer in humans. Positive associations
have been also observed between Cr(VI) exposure and cancer of the
nose and nasal sinuses (IARC, 2012). Exposure to Cr(VI) may occur e.g.
in welding activities (Scheepers et al., 2008), in Cr(VI) electroplating
and other surface treatment activities such as paint application and
removal of old paint containing Cr(VI) (SCOEL, 2017). International
Agency for Research on Cancer (IARC) has recently classified Welding
as carcinogenic to humans (IARC Group 1, IARC, 2018).
Cr(VI) compounds (chromates, chromium trioxide and dichromium
tris(chromate)) are authorized under the European regulation (EC,
1907/2006) concerning the Registration, Evaluation, Authorisation and
Restriction of Chemicals (REACH). According to REACH, all companies
using Cr(VI) compounds have to apply for authorisation for their uses.
More than 100 authorizations for different uses of chromates have al-
ready been requested, some of these covering hundreds of workers,
which means that potentially thousands of workers are exposed to Cr
(VI) in these activities (ECHA, 2019).
REACH concerns only the use of Cr(VI) for specific purposes and
does not cover process-generated fumes like welding fumes. Cr(VI) is
formed, together with the less toxic trivalent chromium (Cr(III)), when
welding metals containing Cr, such as stainless steel (Carre et al., 2005).
Management of Cr(VI) formed during the welding process is achieved
by compliance with occupational exposure limit values (OELs). The
recent binding occupational limit value (BOELV) set under EU Directive
2004/37/EC on the protection of workers from the risks related to
exposure to carcinogens or mutagens at work (EU, 2004) is 0.010mg Cr
(VI)/m3 for a period of 5 years after the date of transposition of the
directive; after that period a limit of 0.005mg Cr(VI)/m3 will apply. For
welding or plasma-cutting processes or similar work processes that
generate fumes, there is a derogation, with an OEL value of 0.025mg Cr
(VI)/m3 until 5 years after the transposition date and after that period
the limit will be 0.005mg Cr(VI)/m3. In France and the Netherlands, an
OEL of 1 μg/m3 has been set for Cr(VI) (MinSZW, 2016; ANSES, 2017).
These are the most stringent OELs currently set for workplaces in the
EU.
1.1. Biomonitoring of Cr(VI)
The common biomarker used for the biomonitoring of Cr exposure
at the workplace is total urinary Cr (U-Cr). Different biological limit
values (BLV) have been set on a national basis in Europe. For example,
the Spanish authorities set a BLV of 10 μg/L for U-Cr measured during a
shift and 25 μg/L at the end of the workweek (INSHT, 2019). In the UK,
a biological monitoring guidance value (BMGV) of 10 μmol/mol crea-
tinine (ca. 6.3 μg/L) in post shift urine has been established (HSE,
2018). France and Finland have derived BLVs of 2.5 μg/L and 10 μg/L
corresponding to their OELs for Cr(VI) (ANSES, 2017; STM, 2018). The
German DFG (Deutsche Forschungsgemeinschaft) has established EKA
values (biological exposure equivalents for carcinogenic substances)
ranging from 12 to 40 μg/L for total Cr at the end of shift in urine and
from 9 to 35 μg/L in the erythrocyte fraction of whole blood at the end
of the shift in the end of the work week. These values correspond to
exposures to 0.03–0.1 mg/m3 soluble alkaline chromate and/or hex-
avalent welding fumes (only for urine) over an 8 h work shift (DFG,
2018).
The main limitation of U-Cr is that it is not specific for Cr(VI) since it
measures exposure to both Cr(III) and Cr(VI). Also, the lowest BLV
given for Cr(VI) (2.5 μg/L in France) is close to background urinary Cr
levels in populations with no known occupational exposure to Cr (e.g.
in France 95th percentile in general population is 0.65 μg/L (ANSES,
2017). These circumstances illustrate the need to develop biomarkers
specifically indicating Cr(VI) exposure. Even if U-Cr remains the most
used approach for routine biomonitoring of Cr(VI) exposure, it is im-
portant to demonstrate how well it correlates with potentially more
specific Cr(VI) exposure biomarkers in different work tasks. Such po-
tential, new exposure biomarkers to Cr(VI) are Cr in red blood cells
(RBC) and Cr(VI) in exhaled breath condensate (EBC).
Cr in RBC (Cr-RBC) reflects mainly the exposure to Cr(VI) since
chromates that contain Cr(VI) can easily permeate through the mem-
brane of the RBC as a tetrahedral divalent anion CrO42−, by using the
same anion transporter as SO42−and PO42- (Ray, 2016). In contrast, Cr
(III) is poorly taken up by erythrocytes (Ray, 2016) at a rate three or-
ders of magnitude lower than Cr(VI). Once Cr(VI) has entered the RBC
it is rapidly reduced to unstable intermediates Cr(V) and Cr(IV) that
bind to the beta chain of human hemoglobin and other ligands forming
a stable Cr-hemoglobin complex. This Cr-hemoglobin complex remains
stable within in the RBC for the cell's lifetime (~120 days)
(Paustenbach et al., 2003). On this basis, Cr can be detected in RBC up
to 120 days following exposure. In addition, Cr(VI) exposure can be
differentiated from Cr (III) exposure by selecting this matrix instead of
measuring Cr from whole blood which includes also Cr derived from the
exposure to Cr(III) (Lewalter et al., 1985).
Cr(VI) in EBC (Cr-EBC) samples has been proposed as a new bio-
marker-matrix combination which can give specific information on the
Cr(VI) levels in the main target tissue i.e. in the lungs (Leese et al.,
2017). It is a less invasive biomarker than blood and Cr(VI) and Cr(III)
can be analysed separately in the EBC samples. However, the possibility
of some reduction of Cr(VI) to Cr(III) has been suggested for this matrix
too, with kinetics not fully explored, yet.
In addition to exposure biomarkers, the characterization of effect
biomarkers is of utmost importance to associate the exposure to Cr(VI)
with its potential impact on human health, given that they comprise
sensitive endpoints that reflect early biochemical changes (subclinical
changes) before the onset of disease (Annangi et al., 2016). In addition,
they may indicate combined effects of different substances, like Cr(VI)
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and nickel (Ni) in welders. Most references have been related to gen-
otoxicity biomarkers. Increased frequency of micronuclei in human
peripheral blood lymphocytes have been shown to be predictive for
cancer risk (Bonassi et al., 2007) and they have consistently shown
correlations with the level of exposure to Cr(VI) (Annangi et al., 2016).
Recently, a flow cytometry-based method has been developed for the
analysis of micronuclei in peripheral blood reticulocytes, allowing a
rapid evaluation of a large number of cells. It is considered very sen-
sitive for the monitoring of genetic damage in humans (Abramsson-
Zetterberg et al., 2000; Abramsson-Zetterberg, 2018). The alkaline
comet assay, on the other hand, allows the identification of a broad
spectrum of primary DNA lesions, such as single- and double-strand
breaks (Azqueta and Collins, 2013) and there are studies reporting in-
creased level of DNA damage measured by the comet assay in workers
exposed to Cr(VI) (e.g. Balachandar et al., 2010; Zhang et al., 2011).
Oxidative stress, inflammation, oxidative DNA lesions, and telomere
damage have been recognized as crucial events in the carcinogenicity
process of many substances, including Cr(VI) (Arita and Costa, 2009;
Annangi et al., 2016). The most used oxidative stress biomarkers in
urine are markers of lipid peroxidation such as malondialdehyde (MDA)
and isoprostanes or markers of DNA damage repair, such as 8-hydro-
xydeoxyguanosine (8-OHdG). Recently, a study showed that urinary 8-
OHdG, and MDA levels in the Cr(VI) exposed electroplating workers
exceeded those in the control subjects (Pan et al., 2017). Cr(VI) ex-
posure has also been suggested to cause telomere damage and guanine
residues of the telomeric repeats seem to be particularly susceptible to
oxidative stress caused by Cr(VI) (Ko et al., 2017). Furthermore, epi-
genetic modifications (e.g. DNA methylation, histone modification)
may contribute to the carcinogenicity of Cr(VI) compounds (Salnikow
and Zhitkovich, 2008; Arita and Costa, 2009; Ray et al., 2014). In vitro,
Cr has been associated with histone modifications in a dose-dependent
manner (Sun et al., 2009; Ray et al., 2014). Also, metabolomic pro-
filing, defined as "the quantitative measurement of the dynamic mul-
tiparametric metabolic response of living systems to pathophysiological
stimuli or genetic modification" (Nicholson et al., 1999) has been sug-
gested to detect overall effects of welding fume exposure (Kuo et al.,
2012; Wei et al., 2013).
1.2. Other hazardous agents in stainless steel welding and surface treatment
activities
In addition to Cr(VI), stainless steel welding produces nickel (Ni)
and manganese (Mn) fumes. Companies performing Cr(VI) electro-
plating, may also apply Ni electroplating. Like Cr(VI), inorganic Ni
compounds are lung carcinogens, for which a health based limit value
of 0.005mg/m3 (respirable fraction) has been recently proposed by
ECHA Risk Assessment Committee (ECHA, 2018). Mn is a neurotoxic
substance for which an indicative occupational exposure limit value
(IOELV) has been also recently updated in the EU (EU, 2017). These
metals are typically measured from the urine and blood samples but
EBC has been suggested as a potential new matrix also for biomoni-
toring of Ni and Mn (Hulo et al., 2014).
In Cr(VI) electroplating, per- and polyfluoroalkyl substances (PFAS)
may be used as mist suppressants to prevent aerosol formation and Cr
(VI) exposure. Several long-chain PFAS have shown bioaccumulative
properties; for example, for perfluorooctane sulfonic acid (PFOS) and
perfluorooctanoic acid (PFOA) as the best-known representatives, with
serum half-lives of 5 and 2–4 years, respectively (EFSA, 2018). Cumu-
lative exposure causes an increase in cholesterol levels and im-
munotoxic effects in humans and also association to reduced birth
weight has been proposed (EFSA, 2018). There is, however, limited
information on the exposure to PFAS in electroplating activities.
2. Aim of the HBM4EU occupational Cr(VI) study
The main aim of this study is to provide EU relevant data on Cr(VI)
internal exposure and early biological effects in occupational settings,
to be used as scientific evidence for regulatory risk assessment and
decision-making under EU chemical legislation and under occupational
safety and health legislation. The second important aim is to evaluate
the capability and validity of different HBM parameters for the specific
assessment of Cr(VI) exposure. This includes specific biomarkers for Cr
(VI) exposure, Cr-RBC and Cr-EBC, as well as biomarkers of early bio-
logical effects, ranging from the classic micronucleus assay to epige-
netics markers.
In addition, the study aims to provide information on welders' and
platers’ exposure to other relevant metals, especially to Ni and Mn, and
of chrome platers exposure to mist suppressants containing PFAS.
This manuscript describes the study protocol, which provides an
integrated model that can be used in future collaborative, multi-na-
tional occupational studies to support decision making in EU or in other
regulatory regimes. Furthermore, it illustrates how the challenges re-
lated to the limitations of national studies regarding smaller sample
sizes, comparability and representability of the results can be resolved.
3. Methodology
3.1. Company and workers recruitment, ethical approvals
Fig. 1 shows the project workflow. The target population includes
workers undertaking activities resulting in occupational exposure to Cr
(VI), e.g. chrome plating, surface treatment by sanding, spraying or
painting, and stainless steel welding. Stainless steel welders were se-
lected since they are expected to be exposed to higher Cr(VI) levels than
mild steel welders. In addition, a control population of workers not
involved in these activities will also be recruited. Samples will be col-
lected from eight countries, namely, Belgium, Finland, France, Italy,
Poland, Portugal, the Netherlands and the United Kingdom (UK).
Companies undertaking the above activities will be invited to par-
ticipate in the study. Control subjects will be selected from companies
in the same geographical area. Worker inclusion and exclusion criteria
for the study are given in Table 1.
Recruitment of the companies and workers follows the standard
operating procedure (SOP) developed under HBM4EU for the selection
of participants, recruitment, informing participants and obtaining in-
formed consent. Interested companies receive an information leaflet,
explaining the aims, objectives of the study and what would be ex-
pected from them and their workers through their participation. If the
company decides to participate an authorized representative completes
an employer certificate of informed consent. Workers involved in the
activities of interest will be approached to express their interest in
participation. An information leaflet for the workers will be distributed
and discussed during the first contact with the workers. Workers will
complete a worker certificate of informed consent if they decide to
participate. The same approach will be followed for controls.
Common information leaflets and informed consent forms, devel-
oped under HBM4EU, have been translated and provided in the na-
tional languages (English, Finnish, French, Polish, Italian, Portuguese
and Dutch). National information, including information on specific
national legislation and the contact details of the relevant national re-
search group have been added. This approach ensures that all the
participating companies and workers receive the same information on
the study.
Study protocols were submitted for approval by medical ethics
boards in each participating country with the necessary approvals being
granted. The informed consent forms will be archived for the entire
study duration and not less than 5 years.
3.2. Standard operating procedures for samplings
In order to collect comparable data in a harmonized way, great
effort has been made in the development of SOPs for the collection,
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handling, sample storage and transfer of the biological and occupa-
tional hygiene samples covered within the Cr(VI) occupational study
(Table 2 and supplementary material 1). These procedures were de-
veloped through active participation of the study team and agreed upon
prior to commencing the measurement campaign, although some were
refined following feedback from initial measurement campaigns un-
dertaken. In addition to the SOPs specific for the chromate study, the
participating countries follow the general HBM4EU sample transfer
protocol and SOPs for the shipment of samples when samples need to be
sent from one laboratory to another.
The developed SOPs aim to minimize pre-analytical problems that
may lead to misrepresentation of the results. Exogenous contamination
introduced by environment and bio-sampling procedures, containers,
reagents, blood preservatives, or physical and chemical changes in the
biomarkers during transport or storage, or changes in the biological
matrix (e.g. coagulation of blood or sedimentation of urine samples) are
the foremost interfering factors on the quality of results. An overview of
the procedures that each participating country is obliged to follow, as
far as is it reasonably possible, are reported in the next sections.
3.3. Sample traceability and collection of contextual information
To guarantee sample traceability, a standardized convention of the
sample code assigned to each worker will be used as unique identifier
for all samples collected. The same coding system is used also for re-
lated documents (questionnaires and informed consent). Two ques-
tionnaires will be used to collect relevant contextual information
(Supplementary material 2). The first being a self-administered ques-
tionnaire to be completed by a company representative, prior to the
sampling campaign. The second is an interviewer-led post-shift worker
questionnaire to be completed while interviewing the worker as close as
Fig. 1. Schematic illustration of the workflow.
Table 1
Worker inclusion and exclusion criteria for the chromate study.
Workers have occupational exposure to Cr(VI) and undertake either surface
treatment (chrome-plating in baths, sanding, spraying or painting) or stainless
steel welding activities.
All genders will be eligible, with ages ranging from 18 to 70 years.
Subjects should be in good health and present at work during the planned period of
the study.
For genotoxicity biomarkers subjects should also fulfill the following inclusion
criteria:
i) are under the age of 50
ii) are non-smokers or ex-smokers for more than six months
iii) have not been subjected to a medical exam such as a medical X-ray or Computerised
Axial Tomography (CAT) scan in the last 3- months
iv) do not suffer or have suffered from cancer.
Table 2
List of detailed SOPs prepared for the study.
SOP No. Title Topic/Sampling matrix
1 Standard operating procedure for selection of participants and recruitment, information to the participants, informed
consent
Recruitment and consent
2 Standard operating procedure for completion of company and worker questionnaires Company and worker questionnaires
3 Standard operating procedure for blood sampling, including sample storage and transfer Blood
4 Standard operating procedure for the collection of exhaled breath condensate samples EBC
5 Standard operating procedure for urine sampling, including sample storage and transfer Urine
6 Standard operating procedure for air sampling of inhalable and respirable dust fraction and (hexavalent) chromium Air
7 Standard operating procedure for obtaining dermal wipe samples Dermal
8 Procedure for comparing occupational hygiene measurements with exposure estimates generated using exposure
models
Contextual exposure determinant information
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possible to the end of work shift.
The company questionnaire aims to collect general information on
the company. Some details regarding general training, exposure mon-
itoring, and occupational health and safety practices are included.
Details of the operational conditions related to their chrome plating,
sanding, spraying or painting tasks and welding operations (as applic-
able) are also obtained through questions on e.g. the amount of Cr(VI)
used, work procedures and frequency of operations leading to metal
exposure, size of the worked parts, and number of involved workers.
The interviewer-led post-shift worker questionnaire is more de-
tailed. Different questionnaires have been prepared for workers in-
volved in chrome plating in baths, welders and surface treatment op-
erators. Job descriptions are addressed through questions concerning
the characteristics of the specific tasks, including their duration in a
work shift, and frequency. Possible background exposures from non-
workplace sources are investigated through the questions related to the
living environment, i.e. rural vs. urban environment, presence of in-
dustrial plants, incinerators or landfill sites, as well as road traffic
density. Information on habits that may affect Cr exposure or effect
marker levels are requested, e.g. cigarette and/or e-cigarette smoking,
tobacco product uses, alcohol consumption, dietary habits and the use
of food supplements (including Cr containing weight loss pills), as well
as recreational activities or hobbies that may lead in Cr exposure.
Presence of dental implants and dental fillings and therapies performed
are investigated as possible confounding factors.
Information on the occupational histories of individual workers, and
a detailed description of the tasks performed on the day of sampling are
collected. Some items are also included to obtain details of the risk
management measures (RMM) used during the work activities, e.g.
presence of local exhaust ventilation (LEV), availability and use of
personal protective equipment (PPE), information and training, hygiene
practices, as well as the occurrence of abnormal conditions during
work.
3.4. Air sampling and sampling of hand wipes
As workers may be exposed to Cr(VI) via the inhalation and dermal
exposure it is important to understand the contribution of each route of
exposure in the total exposure seen by biomonitoring. Personal air
samples will be collected for the assessment of inhalation exposure and
wipe samples to assess skin contamination, which may lead to skin
absorption and to gastrointestinal absorption following hand-to-mouth
exposure (Gorman Ng et al., 2017).
For electroplaters and surface treatment workers, simultaneous
sampling of the inhalable and respirable fractions will be performed
(CEN, 1993). Sampling of the inhalable dust fraction is performed at a
flow rate of 2 L/min with an IOM-sampler containing an IOM-cassette
fitted with a pre-weighed 25mm PVC-filter (GLA-5000). Sampling of
the respirable dust fraction is performed using sampling heads such as
the Higgins Dewell type or similar cyclone sampling heads, performed
at the required flow rate, with these containing a cyclone cassette fitted
with a pre-weighed 25mm PVC-filter (GLA-5000). For welders, alter-
natively the SKC Mini-sampler could be used with a pre-weighed 13mm
MCE filter at a flow rate of 0.75 L/min. Samples will be collected for a
representative period of the work shift (> 75%).
The air samples are to be analysed firstly gravimetrically for de-
termination of the inhalable/respirable dust fraction. The samples are
then analysed for total Cr, Cr(VI) and depending on the activities for
other metals using OSHA Method ID-125G (OSHA, 2002) and ISO
16740 Method (ISO, 2005).
The dermal wipe samples will be collected using SKC Ghost sam-
pling wipes (or similar lead wipes) as these have been demonstrated to
be suitable for the collection of wipe samples for metals, including Cr
(OSHA, 2002; NIOSH, 2003). A standardized wiping technique will be
used to collect samples at set periods during the working shift; these
being pre-shift, first break period, lunch and post-shift. In each
sampling period, using a separate wipe for each hand, five horizontal
and five vertical wipes across the surface of the palm of the hand (in-
cluding the fingers) will be made, followed by a wipe in the clockwise
direction. This procedure will then be repeated for the dorsal region of
the hand, with each finger then being wiped, taking care to wipe in
between the fingers. Field blanks will be collected and comprise of one
wipe handled in the same way as the exposure samples, but were not
used to wipe a hand. The Ghost wipes are to be analysed for total Cr
using OHSA Method ID125G. Average hand areas will be used in sub-
sequent calculations, these being 535 cm2 per male hand (total
1070 cm2 for both hands) and 445 cm2 per female hand (total 890 cm2
for both hands) (EPA, 2011).
3.5. Blood sampling and exposure markers
The collection of blood requires a clean and private space, the
availability of sterile material for blood collection and staff trained in
phlebotomy (WHO, 2010). To reduce interferences in Cr analysis ap-
propriate tubes for trace element detection will be used. In addition, all
the plastic material used for Cr detection are of trace element quality or
soaked in 20% HNO3 for 24 h prior to use and rinsed three times with
deionized distilled water. Regular phlebotomy syringe with a stainless-
steel needle can be used but the use of silicone-coated needle or but-
terfly is recommended.
One blood sample will be collected from each (exposed or non-ex-
posed) worker, preferentially on the 3rd - 5th day of the working week.
Four different tubes are collected: two tubes with sodium heparin for
micronucleus and Comet assays; one with potassium EDTA or heparin
for analysis of Cr in plasma and RBC and PFAS in plasma and one with
potassium EDTA for epigenetics, oxidative stress and telomere length
analyses (see Fig. 2).
To avoid haemolysis in tube 3 (for Cr analysis), plasma and RBC
separation is conducted, preferably within 8 h (and maximum 24 h)
from the specimen collection, following the method described by Devoy
et al. (2016). Samples are centrifuged (10min at 1000–2000×g or
5min at 2700×g) and the supernatant containing the plasma and white
blood cells is used for Cr and PFAS analyses. The pellet undergoes three
washing steps with 0.9% NaCl solution (with a volume corresponding
the initial volume of blood collected), in order to eliminate interfering
plasma/Cr residues. Haematocrit (HT) is measured twice, soon after the
collection (HT1) and just before centrifuging for the last washing (HT2)
and the ratio of HT2:HT1 is calculated for correction of RBC loss along
the washing steps. Analyses can be performed by different analytical
techniques. For instance, the German Research Foundation (Deutsche
Forschungsgemeinschaft, DFG) validated the biomonitoring method
applied in this study by using GFAAS and reaching a detection limit of
0.5 μg/L (DFG, 1990), while a lower detection limit (0.01 μg/L) and
improved accuracy and precision is reached in the case of ICP-MS
quantification (Goldoni et al., 2010).
3.6. EBC samplings and exposure biomarkers
EBC is the collection of cooled exhaled breath as a condensate so-
lution, during regular tidal breathing. This exhaled air is mostly water
vapour, but also droplets of fluid from the respiratory tract. These
droplets of fluid will contain markers and molecules from the mouth,
tracheobronchial system and the alveoli regions of the lungs that ori-
ginate from occupational and environmental exposure (Kharitonov and
Barnes, 2001).
In this study, for the harmonized collection of EBC, we will use
TurboDECCS (Medivac, Parma Italy), in all settings. This is a portable
collection system which consists of a cooling chamber to cool and
condense the exhaled breath sample on the surface of a collection tube
and a sampling system comprising of a mouthpiece connected to a one-
way aspiration valve with a saliva trap.
Two EBC samples will be collected from occupationally exposed
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workers; the first before the start of shift on the first day of the work
week and a second at the end of the shift towards the end of the work
week. For the control group only one EBC sample will be collected (time
not specified).
The collection of EBC is non-invasive and the sampling of EBC does
not cause an inflammatory response itself (Hoffmeyer et al., 2007). EBC
samples are collected by regular, tidal breathing through the mouth via
a disposable mouthpiece for 15min. For the most part, a complete seal
must be maintained around the mouthpiece with periodic swallowing
of saliva.
As the stability and integrity of Cr species can be very dependent on
pH, to inhibit the degradation or interconversion of Cr(III) and Cr(VI)
the EBC sample must be complexed with an EDTA solution and stored
refrigerated (not frozen). Immediately after the collection of each EBC
sample, an aliquot of EBC is diluted 10-fold with 0.5 mM EDTA (pH
adjusted to pH 8 using 10% v/v ammonia solution). In addition, the
volume of EBC collected can vary from one individual to the next. This
variation in EBC sample volume means the concentration of Cr(VI) will
also vary. As there is currently no proposed volume correction marker,
the results will be reported in μg/L per volume of EBC collected.
Therefore, it is important to register the amount of EBC sample ali-
quoted to be complexed with the EDTA solution, and to weigh the re-
mainder of the uncomplexed EBC sample upon return to the analysing
laboratory.
3.7. Urine sample collections and exposure biomarkers
Two spot urine samples will be collected from the occupationally
exposed workers, the first before the start of the shift at the beginning of
the work week, and the second one at the end of the shift towards the
end of the work week. In order to avoid any contamination of urine
samples, participants will be instructed to remove their work clothes
and to thoroughly wash their hands before the urine collection.
Urine samples will be collected in previously decontaminated con-
tainers (pre-washed with 10% of nitric acid solution) to avoid back-
ground contamination. After collection, urine samples will be homo-
genized and aliquoted in several pre-labeled tubes and stored at −20 °C
in freezers before shipment to the analyzing laboratories. Samples will
be analysed for total Cr. Urinary creatinine concentrations will be
measured and Cr results normalized to creatinine. In addition, urinary
Ni and Mn levels will be analysed in urine samples from welders and Ni
in urine samples obtained from workers involved in the use of Ni in
metal plating. These are the main hazardous metals which may be
present at these workplaces besides Cr(VI). Although it is recognized
that urine may not appropriately reflect Mn exposure (Ellingsen et al.,
2006), U-Mn is analysed for comparison together with EBC-Mn levels.
Urine samples will also be analysed for oxidative stress biomarkers
(malondialdehyde, 8-isoprostane, 8-OHdG) and for metabolomic pro-
files.
3.8. Quality assurance
In order to obtain accurate data, the Cr(VI) study will include a
quality assurance (QA) programme in which candidate laboratories for
sample analysis will participate in inter-laboratory comparison in-
vestigations (ICI). The proficiency tests include Cr in urine, RBCs and
plasma and PFAS in plasma. Each laboratory will receive at least two
materials, namely biological specimens, containing the parameters at
different levels. Each control material is tested for stability and
homogeneity by the ICI organizers before distribution. For quantitative
evaluation, the results from the participating laboratories will be rated
using the classical z-scores indicators, according to ISO 13528 (ISO,
2015). Those laboratories that will be successful in the ICI rounds will
be designated qualified to perform analysis of the human samples in
agreement to the HBM4EU Quality Assurance programme criteria
(www.hbm4eu.eu/online-library).
After approval of the candidate laboratories, QA/QC assurance
measures should be maintained concomitant with the analysis of bio-
logical samples. To this end, each laboratory selected for the analysis of
samples has to perform internal quality control (IQC) measures in-
cluding at least the purchase or in-house preparation of appropriate IQC
materials (at least low and high level). The analysis of at least one
sample of each ICQ material in each analytical series and the evaluation
of the IQC results using quality Control Charts (CCs) ensure the
Fig. 2. Blood samples collected.
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comparability of the results over the full study period (Ruggieri et al.,
2016). Sustainable continuation of QA/QC measures beyond the ICI
runs organized in-house by HBM4EU, will be realised by the use of
Certified Reference Materials (CRM) and the participation at public
accessible international proficiency tests, like UK Trace Elements EQAS
(TEQAS, http://www.surreyeqas.org.uk/trace-elements-teqas/), the
Québec multielement EQAS (QMEQAS, https://www.inspq.qc.ca/en/
ctq/eqas) and the German External Quality Assessment Scheme (G-
EQUAS, http://www.g-equas.de/ (Göen et al., 2012)). Since there is no
ICI/EQUAS for Ni and Mn organized under HBM4EU, the laboratories
analysing these elements from urine and blood samples need to parti-
cipate public proficiency tests to ensure the quality of these analyses.
Regarding the analysis of Cr in EBC samples, a suitable ICI/EQUAS
scheme does not exist. One of the aims of HBM4EU will be the devel-
opment and validation of a method for EBC condensate. For this, la-
boratories with previous experience in this technique and capability for
method development will be selected. Once the method is available, a
bespoke QA programme will be designed to ensure the comparability of
the analyses.
3.9. Power calculations and proposed sample sizes
Power calculations were made for urinary Cr to identify the sample
sizes needed to detect meaningful differences between the workers and
controls. Calculations were done by using ClinCalc Sample Size
Calculator (Kane, 2018), which determines the minimum number of
subjects for adequate study power. Study group design was one study
group vs. population, primary endpoint was continuous (means), alpha
was 0.05, and power was either 80% or 95%. Mean (GM) and standard
deviation (SD) of a known population were used in calculations. Ur-
inary total Cr was selected for power calculations because there are
background data available for the general population. For other ma-
trixes the data are scarce. A problem with existing urinary Cr data is
that in most of the published general population studies no SD data is
given. To obtain an estimate on the suitable sample size, we selected
general population data from the UK (Morton et al., 2014) and Italy
(Aprea et al., 2018) as reference populations. In the UK, the GM of the
total urinary Cr is 0.76 μmol/mol creatinine (0.26 μg/L) and GSD
0.55 μmol/mol creatinine (0.24 μg/L). Sample size calculations made
for this study with both 80% and 95% power are shown in Table 3. In
order to detect an increase of 10% in GM of creatinine adjusted urinary
Cr, the required sample size is about 400 (power 80%). For a 20% in-
crease level the respective sample size is about 100 (170 with 95%
power). With non-adjusted urinary Cr concentrations, less than 300
samples are needed to detect a 20% increase in GM. The arithmetic
mean (AM) and SD of the total urinary Cr data from Italy are 0.317 μg/g
creatinine (0.297 μg/L) and 0.334 μg/g creatinine (0.251 μg/L), re-
spectively. In order to detect an increase of 20% in AM of creatinine
adjusted urinary Cr, the required sample size is less than 400 (Table 3).
With non-adjusted urinary Cr concentrations, fewer samples are needed
to detect a 20% increase in AM.
Overall, according to this general population data, 400 samples is a
suitable sample size to reliably detect even small differences between
workers and controls. It was not possible to perform power calculations
for RBC-Cr and EBC-Cr because of the lack of data on background levels
in occupationally non-exposed population. In addition, in the case of
EBC-Cr(VI), background levels in the occupationally non-exposed po-
pulation are typically below the detection limits (Leese et al., 2017).
Also in the case of RBC-Cr, smaller variation in background levels is
expected when compared to the urine total Cr since urine total Cr levels
in occupationally non-exposed population are highly affected also by
the intake of Cr(III) from different sources.
The final target sample sizes for different matrices are shown in
Table 4. Targeted total number of urine samples is 50 pre- and post-shift
samples per country from exposed workers and 25 samples from control
population per country. In the case of EBC and blood, samples will be
collected from 25 exposed workers and 25 controls.
3.10. Data protection, analysis and interpretation
All collected data will be pseudo-anonymized before any treatment,
by replacing participant and company names with a code and pro-
tecting all electronic and paper records from unauthorized access, in
accordance with the EU General Data Protection Regulation (GPDR
Regulation (EU) 2016/679 (http://data.europa.eu/eli/reg/2016/679/
oj). Any information will be presented in a pseudo-anonymous format
so that no external person will be able to identify any person or com-
pany who took part in the study.
Data analyses will be done for HBM biomarker variables and some
main accompanying variables (e.g. age, sex). Data analysis plans for
each specific biomarker include the definition and harmonization of the
variables (codebook), the statistical test to be applied, specific exclu-
sion/partitioning criteria for calculation of reference values, un-
certainty analysis, data descriptions, and visualizations.
A comparison by industry sectors/types of activities (e.g. welding
activities, electroplating and other surface treatment activities) will be
done and data will initially be analysed using a (parametric or non-
parametric, depending on the distribution) two-way ANOVA, with
matching data point. Furthermore, regression models will be developed
for comparison by types of activities, size of companies and/or between
countries, taking into account specific confounders (like sex, age and
tobacco consumption). Multiple linear regression analysis will be
Table 3
Sample size calculations for urinary total chromium.
Reference population Study population
Study Country Units N Mean SD Increase (%) Mean Required sample size
80% power 95% power
Morton et al. (2014) UK μmol/mol creat 297 0.76a 0.55 b 10 0.836 411 681
20 0.912 103 170
μg/L 297 0.26a 0.24b 10 0.286 669 1107
20 0.312 167 277
Aprea et al. (2018) Italy μg/g creat 260 0.317c 0.334d 10 0.3487 871 1443
20 0.3804 218 361
μg/L 260 0.297c 0.251d 10 0.3267 561 928
20 0.3564 140 232
a Geometric mean.
b geometric standard deviation.
c Arithmetic mean.
d Arithmetic standard deviation.
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conducted to examine the associations between inhalation and dermal
exposure and biomarkers.
3.11. Use of inhalation and dermal exposure data for exposure model
testing
More recently, and probably primarily due to regulatory influence
of REACH regulation, the use of predictive exposure models is be-
coming more frequent as it is not possible for the occupational hygiene
community to collect a sufficient number of exposure measurements to
generate estimates for all relevant exposure scenarios (Fransman, 2017;
Landberg et al., 2018). Several Tier 1 screening models such as
ECETOC-TRA, MEASE and others are recommended for use under
REACH (ECHA, 2016) and were evaluated under the E-TEAM project of
which the results have been reported in several papers (Lamb et al.,
2017; Tischer et al., 2017; van Tongeren et al., 2017). Lamb et al. re-
ported a between-user reliability exercise where exposure estimates
ranged over several orders of magnitude for the same exposure situa-
tion by different users (Lamb et al., 2017). It was also noted that the
amount of contextual information provided in the situations could have
potentially affected the level of variation between users. To explore this
further a standardized proforma will be used to collect contextual in-
formation about the work activities observed during the measurement
campaign. At a later stage (and without knowledge of the results of the
measurement campaigns), several experts with different experience on
workplace environments and current activities will be asked to use the
ECETOC TRA v 3, MEASE-2 and ART exposure models to estimate the
inhalation and dermal exposure (where applicable) at the sites, with
these estimates then being compared with the measurement results. The
procedure for this parallel study has been described in SOP No. 8.
3.12. Reporting and participants feedback
The results of the study will be reported within the reporting policy
of the HBM4EU project, and a general report will be publicly accessible
via the project website (https://www.hbm4eu.eu/). It is also antici-
pated that a number of manuscripts outlining the study findings will be
drafted for publication in the peer-reviewed literature.
The participating companies will not receive the results of in-
dividual workers. They will receive results on urinary Cr concentrations
at a group level and on air samplings in a company-specific occupa-
tional hygiene report, which includes any recommendations for the
surveillance and monitoring procedures for the workers, and RMMs
that should be in place to reduce exposure. Since these recommenda-
tions are prepared by the local research teams due consideration can be
given to national regulations and guidelines.
Participants will receive their personal lab results of urinary total Cr
from the research team or occupational physician, depending on the
country specific regulations (unless they have specifically indicated on
their consent form not wanting to receive any individual feed-back). In
some countries this will be done upon request. This will also show if
their result is below or in excess of the national guidance or limit values
for Cr. Participants personal results will be accompanied by a fact sheet
prepared under HBM4EU on Cr(VI). This will provide information
about the possible health effects associated with Cr, the preventative
measures their employer must apply and the precautions they should
take to protect their health when working with Cr.
It is not intended to provide participants or the participating com-
panies with details of their individual blood, EBC and wipe sample
results due to the novelty of the measurement methodology and the
difficulty to compare these results with any legal exposure limits.
However, the collective results of these sampling matrices will be
published in the study report and in various peer-reviewed publica-
tions.
4. Expected results and discussion
To our knowledge, this occupational HBM Cr(VI) study is the first
that will be performed concurrently in multiple European countries
using harmonized protocols for data gathering, sampling and (che-
mical) analyses. So far, most institutes conducted relatively small sur-
veys, but by combining these national standardized surveys, the power
of the study and the strength of the findings are greatly enhanced. This
allows also the comparison of several markers of exposure and effect in
a variety of exposure scenarios while diluting the influence of the in-
dividual workplace visited (which can be an important drawback when
studies are only conducted at one or two sites).
The higher number of companies visited and samples collected will
enhance the usability of the data in regulatory risk assessment and
decision making in EU. The countries involved in the study reflect
different parts of Europe; southern (Italy and Portugal), eastern
(Poland), mid (France, Netherlands and Belgium) and northern parts
(UK and Finland), and the study will also include a range from micro-
sized companies and SMEs to large industries. Since a number of dif-
ferent companies (~40 companies) will be engaged in this study and
detailed contextual information will be collected by the questionnaire,
we will have biomonitoring data linked to different conditions and
different RMMs. This way, data can be collected on the used RMMs and
it will be possible to identify the best practices. In case of reinvestment
or renovation of equipment this information may allow informed de-
cisions to adapt the best available technology.
Hexavalent chromium has been a target for recent legislative actions
in EU. These include authorisation of Cr(VI) under REACH and the
setting of a BOELV for Cr(VI) under CMD. The main challenge in
chromate authorizations has been the paucity of exposure data, parti-
cularly in the case of large applications covering more than hundred
Table 4
Detailed sample collection plan for the eight participating countries.
Samples Sampling period Average number of workers
(per country)a
Average number of controls
(per country)a
Overall Number of samples
(8 countries)
Full Shift Pre-shift/Beginning
work week
Post-shift/End
work week
Urine X X 50 25b 1000
Plasma + RBC At any time in the work week except the first
work day
25 25 400
Whole blood 25 25 400
EBC X X 25 25b 600
Air X 25 – 200
Dermal 4 samples/shiftc 25 – 800
a All matrices will not necessary be collected from all participants.
b One urine and EBC sample from each control.
c Depends on shift duration and number of breaks. In the case of 8 h shift and one lunch and one rest break, wipe samples will be collected pre-shift, first break
period, lunch and post-shift, resulting in four samples per participant.
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individual workplaces. As a self-explanatory example it can be men-
tioned the Chromium Trioxide Authorisation Consortium (CTAC) ap-
plication (ECHA, 2019) where 515 companies based in the EU and 36
different worker contributing exposure scenarios were implicated. To
grant the authorisation, the Risk Assessment Committee of ECHA re-
quested additional exposure monitoring arrangements that should be
based on relevant standard methodologies and be representative of the
range of countries and the range of all those tasks undertaken. There-
fore, the data generated can be used to support exposure assessment in
the scope of the REACH authorisation process, providing background
data for regulators on measured levels in several working contributing
scenarios and related RMMs in European workplaces. Since the sub-
stitution of Cr(VI) in the scope of REACH authorisation is not to be
expected in the near future due to the lack of suitable alternatives for
many uses, the selection of suitable RMM to reduce exposure is very
relevant. Also, very relevant is the comparison of occupational hygiene
measurements with exposure estimates generated using exposure
models since the use of exposure models is the most common practise in
the authorizations processes. This comparison will allow the recogni-
tion of how the contextual information and exposure assessor’s ex-
perience can influence the exposure model outcome. All this can help to
harmonize approaches regarding exposure assessment data available in
authorisation processes to achieve data representativeness.
In the case of stainless-steel welding, the study will inform on the
compliance of companies with the new EU BOELV. This BOELV in-
cludes a derogation for welding or plasma-cutting processes or similar
work processes that generate fumes: only 5 years after the transposition
date the limit will be decreased to 0.005mg/m3. It will be important to
show whether additional RMMs are needed in European welding
workplaces to achieve inhalation exposure levels below 0.005mg/m3
or whether they already are able to comply with it.
Both chromate authorisation and CMD oblige employers to conduct
exposure assessment at the workplaces. Although air monitoring can
provide new and useful information on the airborne levels at the
workplace it does not necessarily give much information on the real
exposure of the workers if PPE is used and is effective. On the other
hand, traditional biomonitoring methods (urinary Cr) may overestimate
the exposure since it cannot differentiate exposure to Cr(VI) from the
exposure to less hazardous Cr(III). This becomes a problem in work
tasks in which co-exposure to different Cr valences occurs (like stainless
steel welding) and also at low OELs, i.e. levels close to an OEL of 1 μg/
m3 established for Cr(VI) in France and the Netherlands. At these ex-
posure levels, corresponding biological limit values are close to back-
ground urinary Cr levels measured in general population (Fréry et al.,
2010; Hoet et al., 2013; Morton et al., 2014; Leng, 2016; Nisse et al.,
2017; Aprea et al., 2018) and an individual’s Cr background level may
have significant impact on total U-Cr level. This means that those
workers with higher backgrounds from other (environmental, dietary
etc.) sources are likely to exceed limit values more readily than those
with lower background levels even though the occupational exposure to
Cr(VI) has been similar. Therefore, new, more specific methods (Cr-EBC
and Cr-RBC) used in the current study can bring more accurate in-
formation on the workers' exposure to Cr and help to improve the oc-
cupational exposure and risk assessment. The result will also bring in-
formation on the reliability of different biomarkers in different work
tasks. It can be hypothesized that U-Cr may be adequate to assess the
exposure to Cr(VI) in plating activities, but not necessarily anymore in
welding activities.
The measurement of Cr-EBC can provide information specifically on
the exposure of the main target organ, lungs, to Cr(VI). Although Cr(VI)
has increased also the risk of local gastrointestinal tract cancers in
animals when administered orally, in humans, lungs remain the main
target organ for its carcinogenic action (ECHA, 2013). Information
obtained from EBC analyses can be used to further refine the assessment
of lung cancer risk in workers exposed to Cr(VI). Correlations between
air Cr(VI), EBC, blood and urinary Cr levels allow further study of the
fate and transformation of Cr(VI) to Cr(III) in the human body. When
EBC-Cr gives us information on the ratio between Cr(VI) and Cr(III) in
mixed exposure scenarios, a simpler U-Cr could be used on a routine
basis and the contribution of Cr(VI) calculated.
The current study also analyses effect markers in blood and urine,
which might bring additional information on the systemic genotoxicity
and epigenetic effects of Cr(VI) at the exposure levels relevant for to-
day’s workplaces. This is useful information when considering the po-
tential systemic carcinogenicity of absorbed Cr(VI). In addition, several
novel effect markers (reticulocyte MN, epigenetic and oxidative stress
markers, telomere length) have been included in the study in order to
evaluate which one is the most sensitive to detect subclinical changes
upon Cr(VI) exposure.
5. Conclusions
This manuscript describes the design of a multicenter study using
HBM in the assessment of Cr(VI) exposure and associated health risks in
occupational settings. It describes in detail the methodology and QA
procedures in a harmonized multicenter study. This biomonitoring
study on occupational exposure to Cr(VI) has a unique set-up including
multiple countries collecting biomonitoring and industrial hygiene in-
formation on exposure to Cr(VI) using harmonized protocols. In this
way, we expect to achieve higher sample numbers than would be fea-
sible in individual studies and create more comprehensive data for EU
decision making. This study has also an important role to test new,
more sensitive and specific methods for the biomonitoring of exposure
to Cr(VI) and their applicability in exposure assessment in occupational
health interventions. The reports of the study results are expected to
become available in 2020.
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